Company Analysis

Elicio Therapeutics, Inc. (ELTX)

Nasdaq: ELTX · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2014
Grade3.8
◀ Past 2.7● Present 3.6▶ Future 4.6
4 est.

Who runs Elicio Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Venkatesan Jay
President and Chief Executive Officer and Director. First filing Feb 2021, latest Sep 2, 2026, 8 filings in all.
Officers reporting now
5
of 11 people with a filing in the last fifteen months
Directors reporting now
6
20 people on the record since 2021
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Venkatesan JayPresident and Chief Executive Officer and DirectorFeb 2021Sep 2, 2026none
Connelly RobertCEO, President and DirectorJun 2023Jul 17, 2026none
Haqq ChristopherExecutive Vice President, Head of R&D and Chief Medical OfficerJun 2023Jul 17, 2026none
Demuth PeterChief Scientific OfficerJun 2023Jul 17, 2026none
Shah PreetamChief Strategy and Financial OfficerApr 2025Jul 17, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Adams JuliandirectorJun 2023Sep 2, 2026none
Ashe Carol GaildirectorJun 2023Sep 2, 2026none
Chudnovsky YekaterinadirectorJun 2023Sep 2, 2026none
Nissenson AllendirectorFeb 2021Sep 2, 2026none
Ruffolo Robert RdirectorJun 2023Sep 2, 2026none
Wilson Karen JdirectorFeb 2021Sep 2, 2026none
Earlier names on the record11, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton ELTX · research, not advice